Local jail awarded grant to help inmates with addiction treatment
This batch of grants, awarded to 13 jails serving a combined 18 counties, expands the program's reach to 26 counties statewide. With the latest payments, the total amount awarded since Yost announced the grants in March stands at more than $3.5 million.
Previously, Trumbull County was awarded $250,000 in the same program.
'Each time I tour a jail with a sheriff who has received a grant, I am encouraged to hear how this funding is going to make a real difference in the fight against addiction,' Yost said. 'Although a jail is no substitute for a rehab center, these grants will aid recovery and support better outcomes for inmates struggling with substance abuse.'
In all, Yost's office is offering $60 million in opioid settlement money over the next several years, with the goal of reducing fatal overdoses in Ohio's jails.
The attorney general's Opioid Remediation Grant Program is awarding county jails up to $200,000 per year to hire a full-time addiction-services coordinator or contract with a company that provides such services to treat opioid and other addictions, helping inmates through detox and recovery. Additionally, any county that operates a jail can apply for a $50,000 grant to fund medications and supplies for inmates experiencing opioid withdrawal.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
What to Expect From Cooper Companies' Q3 2025 Earnings Report
San Ramon, California-based The Cooper Companies, Inc. (COO) develops, manufactures, and markets contact lens wearers. Valued at a market cap of $14.8 billion, the company also focuses on family and women's health care, providing fertility products and services, medical devices, contraception, and cryostorage to health care professionals and patients. It is scheduled to announce its fiscal Q3 earnings for 2025 after the market closes on Wednesday, Aug. 27. Before this event, analysts project this vision and women's healthcare company to report a profit of $1.06 per share, up 10.4% from $0.96 per share in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $0.96 per share in the previous quarter outpaced the consensus estimates by 3.2%. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect COO to report EPS of $4.06, up 10% from $3.69 per share in fiscal 2024. Furthermore, its EPS is expected to grow 9.9% year-over-year to $4.46 in fiscal 2026. Shares of COO have declined 19.8% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 17.3% uptick and the Health Care Select Sector SPDR Fund's (XLV) 9.4% drop over the same time frame. Despite delivering better-than-expected Q2 results on May 29, shares of COO plunged 14.6% in the following trading session. Due to growth in both of its reportable segments, the company's overall revenue improved 6.3% year-over-year to $1 billion, exceeding consensus expectations. Moreover, its adjusted EPS of $0.96 advanced 12.9% from the year-ago quarter, topping analyst estimates by 3.2%. Wall Street analysts are moderately optimistic about COO's stock, with an overall "Moderate Buy" rating. Among 15 analysts covering the stock, 10 recommend "Strong Buy," one indicates a "Moderate Buy," and four advise 'Hold.' The mean price target for COO is $92.93, implying a 25.9% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 hours ago
- Business Wire
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for sebetralstat, a novel oral plasma kallikrein inhibitor, for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The European Commission (EC) final decision is expected by early October. 'This positive CHMP opinion is an important step forward for people living with HAE in Europe, where there remains a high need for effective, easy-to-administer on-demand treatments,' said Ben Palleiko, CEO of KalVista. 'Coming just weeks after regulatory approvals in the US and UK, this milestone highlights the potential of sebetralstat to transform how HAE is managed globally. Sebetralstat is expected to become the first and only oral on-demand treatment for HAE available in Europe, bringing forward a new treatment approach that enables adherence to guidelines and empowers people to treat attacks quickly, wherever they occur.' The CHMP based its opinion on results from the phase 3 KONFIDENT clinical trial, which was the largest clinical trial ever conducted in HAE. Data from KONFIDENT was published in the New England Journal of Medicine in May 2024, showing that sebetralstat achieved significantly faster symptom relief, reduction in attack severity and attack resolution than placebo, and was well-tolerated with a safety profile similar to placebo.1 The trial randomized 136 HAE patients from 66 clinical sites across 20 countries. 'Access to on-demand treatments that offer easy self-administration and rapid symptom relief is critical for patients living with HAE,' said Emel Aygören-Pürsün, M.D., Assistant Professor, Internal Medicine and Hemostaseology, Department for Children and Adolescents, University Hospital Frankfurt. 'Until now, on-demand therapies for HAE attacks required parenteral administration via injections. The positive CHMP opinion for sebetralstat is an essential move toward a novel, long-awaited oral on-demand option that could help patients treat attacks early and independently, as advocated by guidelines, with the goal of improving outcomes and normalizing lives.' Sebetralstat is approved in the United States and United Kingdom under the brand name EKTERLY® for the treatment of HAE attacks in people 12 years of age and older. It is currently under review with regulatory authorities in Japan as well as multiple other territories. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity. About Sebetralstat Sebetralstat is a novel plasma kallikrein inhibitor approved in the United States and United Kingdom for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is the first and only oral on-demand treatment for HAE. With ongoing studies exploring its use in children aged two to 11 and multiple regulatory applications under review in key global markets, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. U.S. INDICATION AND IMPORTANT SAFETY INFORMATION What is EKTERLY® (sebetralstat)? EKTERLY is a prescription medicine used to treat sudden (acute) attacks of hereditary angioedema (HAE) in adults and children aged 12 years of age and older. It is not known if EKTERLY is safe and effective in children under 12 years of age. IMPORTANT SAFETY INFORMATION Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you: Are pregnant or planning to become pregnant. It is not known if EKTERLY can harm your unborn baby. Are breastfeeding or plan to breastfeed. It is not known if EKTERLY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking EKTERLY. Have liver problems. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking EKTERLY with certain other medicines can cause side effects or affect how well EKTERLY or the other medicines work. Especially tell your healthcare provider if you take any of the following, as their use with EKTERLY is not recommended: itraconazole, phenytoin, efavirenz. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. What are the possible side effects of EKTERLY? The most common side effects of EKTERLY include headache. For more information, ask your healthcare provider or pharmacist. Talk to your doctor for medical advice about side effects. You are encouraged to report side effects related to KalVista products by calling 1-855-258-4782. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit or call 1-800-FDA-1088. Please click here for full Prescribing Information, including Patient Information. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, information relating to our business and business plans, the success of our efforts to commercialize EKTERLY® (sebetralstat), our ability to successfully obtain foreign regulatory approvals for sebetralstat, including approval by the EC, our expectations about the timing of the EC's final decision, our expectations about the safety and efficacy of sebetralstat and our other product candidates, the timing of clinical trials and their results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and the ability of EKTERLY to treat HAE. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2025, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. _______________________ Expand 1Riedl MA, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391(1):32–43. Expand
Business Wire
4 hours ago
- Business Wire
Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Venova Technologies, Inc., a women-led startup developing a novel long-acting, hormone-free and copper-free female birth control device, has been awarded a $2.23M Small Business Innovation Research (SBIR) Phase II Grant from the National Institutes of Health (NIH). The SBIR program is a highly competitive, awards-based program designed to stimulate technological innovations developed by U.S. small businesses on a path to commercialization. This Phase II award accelerates the preclinical development of Venova's innovative cervical barrier device toward first-in-human clinical studies and brings the company's total funding to over $5M. According to a UCLA survey, 73% of women want a birth control method that is very effective and has limited side effects, but this does not currently exist. A 2023 study found that half of women will stop or switch their birth control method because of unwanted or adverse side effects. 'This award is a pivotal milestone that brings us one step closer to offering a new birth control option for women that is designed to be side-effect-free and addresses concerns of pain from IUD insertion,' said Emily Man, Co-Founder & CEO of Venova. 'Validation from the scientific community highlights the growing momentum and critical need for innovation in women's health.' 'It's more important than ever to provide a wide range of choices for contraception that can meet the needs of more patients,' said Dr. Katharine White, Chair of Obstetrics and Gynecology at Boston University Chobanian & Avedisian School of Medicine and Chief of Obstetrics and Gynecology for the Boston Medical Center Health System. Dr. White is also the Chief Medical Advisor at Venova. 'Offering more affordable options that address a variety of preferences will enable more women to achieve the family size that they truly desire.' About Venova Technologies Venova Technologies, Inc., is a women-led startup dedicated to empowering women to take full control over their reproductive health. The company is developing a novel long-acting female contraceptive barrier device. Headquartered in Cambridge, Mass., at The Engine built by MIT, Venova participates in this premier ecosystem for high-potential, Tough Tech startups. For more information, visit Follow Venova on LinkedIn at
